Friday, October 24, 2025
  • Who’sWho Africa AWARDS
  • About TimeAfrica Magazine
  • Contact Us
Time Africa Magazine
  • Home
  • Magazine
  • WHO’SWHO AWARDS
  • News
  • World News
    • US
    • UAE
    • Europe
    • UK
    • Israel-Hamas
    • Russia-Ukraine
  • Politics
  • Crime
  • Lifestyle
  • Sports
  • Column
  • Interviews
  • Special Report
No Result
View All Result
Time Africa Magazine
  • Home
  • Magazine
  • WHO’SWHO AWARDS
  • News
  • World News
    • US
    • UAE
    • Europe
    • UK
    • Israel-Hamas
    • Russia-Ukraine
  • Politics
  • Crime
  • Lifestyle
  • Sports
  • Column
  • Interviews
  • Special Report
No Result
View All Result
Time Africa Magazine
No Result
View All Result
  • Home
  • WHO’SWHO AWARDS
  • News
  • Magazine
  • World News

Home » Health » Philanthropies Strike a Promising Deal to Turn Back H.I.V.

Philanthropies Strike a Promising Deal to Turn Back H.I.V.

Low- and middle-income countries will be able to purchase an effective preventative at a reduced price. The arrangements may help stem the epidemic 40 years after it began | By APOORVA MANDAVILLI

September 25, 2025
in Health
0
A vial of lenacapavir, the twice-yearly injectable H.I.V. prevention drug marketed as Yeztugo.Credit...Nardus Engelbrecht/Associated Press

A vial of lenacapavir, the twice-yearly injectable H.I.V. prevention drug marketed as Yeztugo.Credit...Nardus Engelbrecht/Associated Press

542
SHARES
4.5k
VIEWS
Share on FacebookShare on Twitter

A drug that provides near-perfect protection against H.I.V. with shots just twice a year will be made available at $40 per patient annually in low- and middle-income countries, offering new hope for ending the H.I.V. epidemic.

Although current treatments can suppress H.I.V., there is no real cure, making affordable prevention crucial for turning back the virus. About 1.3 million people worldwide become infected with H.I.V. every year.

The drug, lenacapavir, is given as two shots every six months. Through two deals announced on Wednesday by philanthropic organizations, the shots would cost the same as daily oral pills to prevent H.I.V., making lenacapavir a realistic choice in countries with constrained resources.

“This is a game-changer,” said former President Bill Clinton, co-founder and chair of the board of the Clinton Health Access Initiative, which helped negotiate one of the new partnerships.

ReadAlso

These are the early signs and symptoms of womb cancer you need to look out for

Almost all heart attack victims have one of these four warning signs

”It simplifies prevention for patients, doctors, and health systems alike,” he said.

Health ministers of African countries welcomed news of a lower price.

ADVERTISEMENT

“By making lenacapavir available soon for just $40 a year, we’re seeing remarkable progress in long-acting H.I.V. prevention,” Rwanda’s health minister, Dr. Sabin Nsanzimana, said.

Yet the deals come at a time when deep cuts to global health programs are forcing low- and middle-income countries to make tough decisions about how to fund responses to their most urgent health priorities, including malaria, tuberculosis and malnutrition.

“Where are those dollars and rands and shillings going to come from to actually procure the product, even if it’s $40 per person per year?” said Mitchell Warren, executive director of the H.I.V. prevention organization AVAC.

Oral pills are extremely effective at preventing H.I.V. But many people find daily medication difficult. Concerns about safety, privacy and stigma also create obstacles, particularly for women, in low-income countries.

Long-acting drugs largely circumvent those hurdles. Lenacapavir, made by Gilead Sciences, is the second long-acting option for H.I.V. prevention. An alternative, cabotegravir (brand name: Apretude), is injected every two months and is made by ViiV Healthcare, GSK’s H.I.V. company.

Lenacapavir’s twice-yearly injections, with an effectiveness of more than 99 percent in clinical trials, have inspired enormous optimism.

“We have the recipe here for a really successful once-in-a-lifetime shift in the way we’ve done H.I.V. prevention, and that’s really exciting,” said Jirair Ratevosian, a senior fellow at the Duke Global Health Institute.

Both long-acting drugs had seemed out of reach for most countries. In June, when lenacapavir was approved in the United States, Gilead said the drug would be marketed as a preventative called Yeztugo at a list price of $28,218.

The list price for cabotegravir is comparable. British researchers have estimated that lenacapavir could be made for as little as $40 per patient per year.

Gilead announced last October that it would allow six companies to make generic copies of the drug for 120 low- and middle-income countries. The new price of $40 per patient annually will be available in only those countries.

Unitaid, an international organization that aims to make lifesaving drugs affordable, along with the Clinton Health Access Initiative and the research institute Wits RHI, negotiated a partnership with Dr. Reddy’s Laboratories, a generics manufacturer in India.

The Gates Foundation forged a second deal for lenacapavir with Hetero, also based in India and the largest manufacturer of H.I.V. drugs worldwide. Although the partnerships were negotiated separately, the organizations aligned their efforts, including the timing of their announcements.

“What we want is to have a generic market that is the right size, the right price, but also to have some competition” between manufacturers, Dr. Philippe Duneton, executive director of Unitaid, said.

Carolyn Amole, a vice president at the Clinton Health Access Initiative, said the $40 price was only a start.

“What we have done with this price agreement is get the product on a pathway to even further price reduction and greater affordability,” she said, adding that the lower price will move countries toward the goal of self-reliance.

Generic versions of lenacapavir will be available starting in 2027. The Global Fund and the President’s Emergency Plan for AIDS Relief, or PEPFAR, have also announced a plan to distribute lenacapavir to 2 million people by 2028 in up to a dozen countries.

But about 40 million people need to take preventive drugs to achieve epidemic control in sub-Saharan Africa, according to some estimates.

PEPFAR has funds appropriated for prevention that could provide ”bridge” funding until the generics kick in, said Asia Russell, executive director of the advocacy group Health GAP.

The State Department’s “vanity project” to get the drug to 2 million people will make barely a dent in that need, she added: “The U.S. has responded to the science with a whimper instead of a roar.”

The State Department did not immediately respond to a request for comment.

The new deals do not include some middle- and high-income countries, including Brazil, that together account for about 20 percent of new infections.

“The rest of the world needs to benefit from that price as well,” Ms. Russell said.

Bill and Melinda Gates Foundation, President’s Emergency Plan for AIDS Relief, Gilead Sciences Inc

Tags: AIDSH.I.V.HealthLenacapavir
ADVERTISEMENT
Previous Post

Malawi President Concedes Election to His Predecessor

Next Post

‘Miracle’ HIV drug to be sold at knock-down price in over 100 countries

You MayAlso Like

Health

The common vegetable that can lower blood pressure in just two weeks

October 15, 2025
Health

These are the early signs and symptoms of womb cancer you need to look out for

October 12, 2025
Image credit: Africa Studio
Health

Almost all heart attack victims have one of these four warning signs

October 12, 2025
Health

Blind Mother and Daughter Look into Each Others’ Eyes for the First Time

October 10, 2025
Health

Poor sleep could make your brain age faster, study finds

October 3, 2025
Health

‘Miracle’ HIV drug to be sold at knock-down price in over 100 countries

September 25, 2025
Next Post

‘Miracle’ HIV drug to be sold at knock-down price in over 100 countries

Trump warns US cities he will move World Cup games if they aren’t ‘safe’

Discussion about this post

Open Letter to the Enugu State Commissioner for Local Government and Chieftaincy Affairs

PDP Chairmanship Position: Odds Favour Tanimu Turaki

Coup Rumours Are False — Nigerian Defence Headquarters

Finally, Family Confirms Death of Rev. Dr. Uma Ukpai, Dies at 80

NITEL, Now Ntel, Set for 2026 Comeback

ASUU suspends two-week warning strike

  • British government apologizes to Peter Obi, as hired impostors, master manipulators on rampage abroad

    1242 shares
    Share 497 Tweet 311
  • Maids trafficked and sold to wealthy Saudis on black market

    1068 shares
    Share 427 Tweet 267
  • Flight Attendant Sees Late Husband On Plane

    975 shares
    Share 390 Tweet 244
  • ‘Céline Dion Dead 2023’: Singer killed By Internet Death Hoax

    905 shares
    Share 362 Tweet 226
  • Crisis echoes, fears grow in Amechi Awkunanaw in Enugu State

    738 shares
    Share 295 Tweet 185
  • Trending
  • Comments
  • Latest

British government apologizes to Peter Obi, as hired impostors, master manipulators on rampage abroad

April 13, 2023

Maids trafficked and sold to wealthy Saudis on black market

December 27, 2022
Flight Attendant Sees Late Husband On Plane

Flight Attendant Sees Late Husband On Plane

September 22, 2023
‘Céline Dion Dead 2023’: Singer killed By Internet Death Hoax

‘Céline Dion Dead 2023’: Singer killed By Internet Death Hoax

March 21, 2023
Chief Mrs Ebelechukwu, wife of Willie Obiano, former governor of Anambra state

NIGERIA: No, wife of Biafran warlord, Bianca Ojukwu lied – Ebele Obiano:

0

SOUTH AFRICA: TO LEAVE OR NOT TO LEAVE?

0
kelechi iheanacho

TOP SCORER: IHEANACHA

0
Goodluck Ebele Jonathan

WHAT CAN’TBE TAKEN AWAY FROM JONATHAN

0

NITEL, Now Ntel, Set for 2026 Comeback

October 22, 2025

ASUU suspends two-week warning strike

October 22, 2025

PDP: Why Tanimu Turaki Holds the Key to Party Rebirth

October 20, 2025

2025 PDP Convention: History Beckons on Tanimu Turaki

October 19, 2025

ABOUT US

Time Africa Magazine

TIMEAFRICA MAGAZINE is an African Magazine with a culture of excellence; a magazine without peer. Nearly a third of its readers hold advanced degrees and include novelists, … READ MORE >>

SECTIONS

  • Aviation
  • Column
  • Crime
  • Europe
  • Featured
  • Gallery
  • Health
  • Interviews
  • Israel-Hamas
  • Lifestyle
  • Magazine
  • Middle-East
  • News
  • Politics
  • Press Release
  • Russia-Ukraine
  • Science
  • Special Report
  • Sports
  • TV/Radio
  • UAE
  • UK
  • US
  • World News

Useful Links

  • AllAfrica
  • Channel Africa
  • El Khabar
  • The Guardian
  • Cairo Live
  • Le Republicain
  • Magazine: 9771144975608
  • Subscribe to TIMEAFRICA MAGAZINE biweekly news magazine

    Enjoy handpicked stories from around African continent,
    delivered anywhere in the world

    Subscribe

    • About TimeAfrica Magazine
    • Privacy Policy
    • Contact Us
    • WHO’SWHO AWARDS

    © 2025 TimeAfrica Magazine - All Right Reserved. TimeAfrica Magazine Ltd is published by Times Associates, registered Nigeria. Use of this site constitutes acceptance of our Terms of Service.

    No Result
    View All Result
    • WHO’SWHO AWARDS
    • Politics
    • Column
    • Interviews
    • Gallery
    • Lifestyle
    • Special Report
    • Sports
    • TV/Radio
    • Aviation
    • Health
    • Science
    • World News

    © 2025 TimeAfrica Magazine - All Right Reserved. TimeAfrica Magazine Ltd is published by Times Associates, registered Nigeria. Use of this site constitutes acceptance of our Terms of Service.

    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.